Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

Stopped early · Phase 2 · Has a placebo group

Conditions studied: COVID, ARDS

In brief

This clinical trial will examine if a new treatment of Mesenchymal-like Adherent stromal Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover more quickly with less complications.

Key facts

Study ID

NCT04389450

Run by

Pluristem Ltd.

People needed

66

Starts

2020-10-01

Expected to finish

2023-06-07

Last updated by the study team

2024-08-30

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Southern California (USC) - Keck School of Medicine (KSOM) — Los Angeles, California, United States
• University Of California Davis,4860 Y Street — Sacramento, California, United States
• Baptist Health Medical Center — Jacksonville, Florida, United States
• Medical College of Georgia at Augusta University — Augusta, Georgia, United States
• Sarah Cannon Research Institute, LLC (Mercer University School of Medicine) — Macon, Georgia, United States
• University of Mississippi Medical Center — Jackson, Mississippi, United States
• Cooper Research Institute — Camden, New Jersey, United States
• Holy Medical Center — Teaneck, New Jersey, United States
• Montefiore Medical Center — New York, New York, United States
• Maimonides Medical Center — New York, New York, United States
• Mercy Medical Center — New York, New York, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• University of California Irvine — Irvine, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.